Understanding how damaged mitochondria are cleared in heart disease related to diabetes
Rab GTPases-mediated mitochondrial clearance in diabetic cardiomyopathy
['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-10824226
This study is looking at how diabetes affects the heart by exploring how damaged parts of heart cells are cleaned out, which could help find new ways to keep hearts healthier for people with diabetes.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-10824226 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms behind diabetic cardiomyopathy, a serious heart condition that affects patients with diabetes. It focuses on how damaged mitochondria, which can lead to further cell damage and heart failure, are removed from heart cells. By studying patient-specific stem cells, the research aims to uncover a novel pathway for mitochondrial degradation that may be impaired in diabetic patients. The findings could help identify new therapeutic targets to improve heart health in those with diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with diabetes, particularly those experiencing heart issues related to diabetic cardiomyopathy.
Not a fit: Patients without diabetes or those whose heart conditions are unrelated to diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve heart function and reduce the risk of heart failure in diabetic patients.
How similar studies have performed: Other research has shown promise in understanding mitochondrial dysfunction in diabetes, but this specific approach to mitochondrial clearance is novel.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ONG, SANG GING — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: ONG, SANG GING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Vascular Hypertensive Disorder, hypertensive disease, hypertensive disorder